Diabetes Mellitus, Type 2
Conditions
Keywords
Retrospective, Type 2 Diabetes, Cost Analysis, Rosiglitazone, Sitagliptin
Brief summary
This retrospective database study analyzed resource utilization and costs associated with sitagliptin (STG) in comparison with rosiglitazone (RSG) added to metformin (MET) monotherapy among adults with a diagnosis of diabetes who were continuously enrolled in a large US healthcare plan.
Interventions
DRUGRosiglitazone + Metformin
At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
At least 180 days of continuous therapy with STG+MET after the first Rx for STG
Sponsors
GlaxoSmithKline
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Continuously enrolled in the health insurance plan to ensure complete claims coverage * At least 1 claim with a diagnosis of diabetes (ICD-9 250.xx) * Aged 18 years or older at the index date * At least 6 months of baseline period prior to the index date * At least 1 claim for MET during the baseline period * At least 180 days of continuous therapy with RSG+MET or STG+MET after the index date
Exclusion criteria
* At least 1 claim for insulin or sulfonylurea in the baseline period * At least 1 claim with a diagnosis of congestive heart failure in the baseline period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| medical resource utilization | at least 12 months following first prescription with RSG or STG as an add-on therapy to MET monotherapy. | Direct healthcare and indirect sick leave costs |
Outcome results
None listed